GEMINI THERAPEUTICS INC (GMTX)

US36870G1058 - Common Stock

1.35  0 (0%)

After market: 1.32 -0.03 (-2.22%)

Fundamental Rating

3

Taking everything into account, GMTX scores 3 out of 10 in our fundamental rating. GMTX was compared to 588 industry peers in the Biotechnology industry. GMTX has a great financial health rating, but its profitability evaluates not so good. GMTX has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GMTX has reported negative net income.
GMTX had a negative operating cash flow in the past year.

1.2 Ratios

The profitability ratios for GMTX are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

GMTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, GMTX has more shares outstanding
GMTX has a worse debt/assets ratio than last year.

2.2 Solvency

GMTX has an Altman-Z score of 21.03. This indicates that GMTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of GMTX (21.03) is better than 94.57% of its industry peers.
There is no outstanding debt for GMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.03
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

GMTX has a Current Ratio of 71.49. This indicates that GMTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 71.49, GMTX belongs to the best of the industry, outperforming 99.53% of the companies in the same industry.
A Quick Ratio of 71.49 indicates that GMTX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 71.49, GMTX belongs to the best of the industry, outperforming 99.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 71.49
Quick Ratio 71.49

More info and screens

1

3. Growth

3.1 Past

GMTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.64%, which is quite impressive.
EPS 1Y (TTM)29.64%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q82.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 12.85% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.97%
EPS Next 2Y36.14%
EPS Next 3Y23.09%
EPS Next 5Y12.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GMTX. In the last year negative earnings were reported.
Also next year GMTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as GMTX's earnings are expected to grow with 23.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.14%
EPS Next 3Y23.09%

More info and screens

0

5. Dividend

5.1 Amount

GMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GEMINI THERAPEUTICS INC

NASDAQ:GMTX (12/29/2022, 7:00:02 PM)

After market: 1.32 -0.03 (-2.22%)

1.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap58.45M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 71.49
Quick Ratio 71.49
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)29.64%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y81.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y